Welcome to our dedicated page for Belite Bio SEC filings (Ticker: BLTE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Belite Bio, Inc. filings document foreign-issuer disclosures for a clinical-stage biopharmaceutical company developing tinlarebant for degenerative retinal diseases. Form 6-K reports furnish press releases on clinical-trial progress, FDA-related regulatory updates, financial results, annual-report availability, material agreements, shareholder matters, and capital-structure activity involving American Depositary Shares.
The company's Form 20-F reporting framework covers audited consolidated financial statements and public-company disclosure for BLTE as a foreign private issuer. Its filing record centers on STGD1, geographic atrophy in advanced dry AMD, tinlarebant development, financing activity, governance matters, and the incorporation of furnished reports into effective Securities Act registration statements.
Belite Bio director Wan-Shan Chen sold 1,100 American depositary shares in an open-market transaction. The sale took place on April 9, 2026 at an average price of $180.4301 per ADS. After this sale, Chen directly holds 9,096 ADS. Each ADS represents one ordinary share of Belite Bio. The transaction was executed under a Rule 10b5-1 trading plan that Chen adopted on December 23, 2025, indicating the sale was pre-arranged rather than timed at discretion.
Belite Bio, Inc.'s Chief Financial Officer Hao-Yuan Chuang reported open-market sales of a total of 6,200 American depositary shares on April 9, 2026. The sales were executed in multiple trades at weighted average prices ranging from about $180.35 to $183.08, pursuant to a pre-established Rule 10b5-1 trading plan adopted on December 22, 2025. Following these transactions, Chuang directly holds 93,800 American depositary shares, which each represent one ordinary share of the company.
BLTE submitted a Form 144 notifying the proposed sale of American Depositary Shares (each representing one ordinary share). The filing lists multiple recent acquisitions via ESOP exercise and RSU vesting, including transactions of 42,811, 15,113, 7,909, 11,388, and two 20,000-share entries, dated through 11/03/2025.
BLTE submitted a Rule 144 notice to sell 100,000 American Depositary Shares. The filing lists the sale as tied to an ESOP exercise with an executed date of 03/20/2025 and a cash transaction date of 03/19/2025. The cover data shows numeric entries 39,339,960 and 17,873,000 with an associated date of 04/09/2026.
Belite Bio, Inc. submitted Form 144 entries that show exercises-and-hold of stock options resulting in 1,400 shares on 08/26/2024 and 8,796 shares on 02/26/2025. The filing lists Common Stock and identifies J.P. Morgan Securities LLC as a broker.
Belite Bio director Chen Wan-Shan reported a compensation-related stock option award. On 3/31/2026, Chen acquired options to purchase 13,796 ordinary shares at an exercise price of 0.4386 per share, expiring on 12/22/2030.
According to the disclosure, these options stem from a grant originally issued on 12/23/2020 that vests upon meeting specific performance criteria. One such criterion was achieved on 3/31/2026, causing 13,796 additional ordinary shares to vest under the option. This is not an open-market buy or sell but a performance-based equity award.
Belite Bio’s Chief Financial Officer Hao-Yuan Chuang acquired additional vested stock options tied to performance goals. On the satisfaction of a performance criterion on March 31, 2026, an option vested as to 144,868 ordinary shares under a grant originally made on December 23, 2020.
The option has an exercise price of $0.4386 per share and an expiration date of December 22, 2030. After this vesting event, the CFO holds options exercisable for a total of 289,736 ordinary shares under this grant.
Belite Bio Chief Scientific Officer Nathan L. Mata had additional stock options vest tied to performance goals. An existing option grant from April 18, 2022 vested as to 144,868 ordinary shares on March 31, 2026 after a performance criterion was met.
The vested option covers ordinary shares at an exercise price of $6.00 per share and now totals 267,934 exercisable shares, including 123,066 shares that had previously vested. This is a compensation-related award, not an open-market stock purchase or sale.
Belite Bio director and CEO Yu-Hsin Lin reported a vesting-related stock option event tied to performance goals. On March 31, 2026, one of the performance criteria for a previously granted option was met, causing an additional 206,954 ordinary shares subject to the option to vest at an exercise price of $0.4386 per share.
This award was originally granted on December 23, 2020 and vests in installments upon meeting specific performance conditions. Following this vesting event, Lin holds options covering a total of 413,908 ordinary shares, all at the same exercise price, as part of compensation rather than an open-market trade.
Belite Bio, Inc has made its annual report on Form 20-F, which includes audited consolidated financial statements for the year ended December 31, 2025, available through its website. Shareholders can request a hard copy of the report free of charge.
The company is a clinical-stage drug developer targeting degenerative retinal diseases such as Stargardt disease type 1 and geographic atrophy in dry age-related macular degeneration. Its lead oral candidate, tinlarebant, has completed a Phase 3 trial in adolescent STGD1 and is in ongoing Phase 2/3 and Phase 3 studies.